Clinical TrialJul 27, 2026, 04:02 PM
ProMIS Neurosciences to Discuss PMN310 Phase 1b Interim Data
AI Summary
ProMIS Neurosciences Inc. announced it will host a webinar on July 28, 2026, to discuss six-month blinded interim data from its PRECISE-AD Phase 1b trial for PMN310 in early Alzheimer's disease. The discussion will feature Key Opinion Leaders Dr. Will Mantyh and Dr. Michael Weiner, alongside company leadership, focusing on aggregate safety data and biomarker trends. PMN310, a lead product candidate, is designed to selectively target toxic amyloid-beta oligomers and received FDA Fast Track Designation in July 2025.
Key Highlights
- ProMIS Neurosciences to host a webinar on July 28, 2026, at 8:00 am ET.
- Webinar will discuss six-month blinded interim data from PRECISE-AD Phase 1b trial.
- Data analysis will focus on blinded aggregate safety and overall trends in select biomarkers.
- Key Opinion Leaders Dr. Will Mantyh and Dr. Michael Weiner will join company leadership.
- PMN310 is a humanized IgG1 monoclonal antibody targeting toxic oligomers of amyloid-beta.
- PMN310 received FDA Fast Track Designation in July 2025.
- PRECISE-AD Phase 1b trial has enrolled 144 participants across three dosing cohorts.
Price Impact
More from PMN